The Tumor Quant service utilizes 3D imaging to differentiate between residual tumor tissue and treatment-induced damage, such as radiation necrosis, in patients with high-grade gliomas. Traditional MRI scans often struggle to make this distinction, complicating the assessment of treatment effectiveness.
Our approach integrates blood flow data from perfusion imaging with detailed MRI enhancement data. This combination generates a map of the tumor, useful for distinguishing actual tumor tissue from necrotic areas. Such accuracy is important for tailoring patient treatment plans, allowing doctors to make informed decisions regarding subsequent care steps.
The primary medical justification stems from the need for precise tumor characterization and treatment monitoring in patients with high-grade gliomas and other tumors. This precision directly impacts treatment planning, effectiveness, and outcomes. By differentiating between tumor tissue and treatment effects such as radiation necrosis, clinicians can make more informed decisions regarding ongoing treatment strategies, potentially improving patient outcomes. Link to Justification
Types:
Graphic Reports
Advanced
Quantitative Measurements